Avanir Pharmaceuticals (NASDAQ:AVNR) posted its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.02, American Banking News.com reports. The company had revenue of $21.70 million for the quarter, compared to the consensus estimate of $21.86 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 60.7% on a year-over-year basis.
Avanir Pharmaceuticals (NASDAQ:AVNR) opened at 4.29 on Wednesday. Avanir Pharmaceuticals has a one year low of $2.34 and a one year high of $6.00. The stock’s 50-day moving average is $4.3 and its 200-day moving average is $4.50. The company’s market cap is $624.1 million.
Several analysts have recently commented on the stock. Analysts at Mizuho downgraded shares of Avanir Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday. They now have a $5.00 price target on the stock, down previously from $11.00. Analysts at Wedbush reiterated an “outperform” rating on shares of Avanir Pharmaceuticals in a research note to investors on Thursday, September 12th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $10.10.
AVANIR Pharmaceuticals, Inc (NASDAQ:AVNR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.